Clinical Trial Update: Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating two PSMA-targeted radioligands, [177Lu]Lu-PSMA-R2 and [225Ac]Ac-PSMA-R2, in PSMA-positive prostate cancer participants has been wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• [177Lu]Lu-PSMA-R2
• [225Ac]Ac-PSMA-R2

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: WITHDRAWN